Enzymotec Ltd
ENZY
ENZY was delisted on the 10th of January, 2018.
30 hedge funds and large institutions have $95.2M invested in Enzymotec Ltd in 2015 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
20% more funds holding
Funds holding: 25 → 30 (+5)
14% more capital invested
Capital invested by funds: $83.4M → $95.2M (+$11.8M)
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TM
Tiger Management
New York
|
+$3.39M |
| 2 |
Renaissance Technologies
New York
|
+$679K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$632K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$352K |
| 5 |
Morgan Stanley
New York
|
+$315K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPPAM
Summit Partners Public Asset Management
Boston,
Massachusetts
|
-$874K |
| 2 |
Millennium Management
New York
|
-$442K |
| 3 |
RCM
Rotella Capital Management
Bellevue,
Washington
|
-$155K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$84.7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$42K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PCM
26
Penserra Capital Management
Orinda,
California
| $13K | +$13K | +1,374 | New |
|
|
AIG
27
American International Group
New York
| $8K | – | – | – |
|
28
Royal Bank of Canada
Toronto,
Ontario, Canada
| $3K | – | – | – |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| $1K | -$568 | -60 | -29% |
|
|
SPPAM
30
Summit Partners Public Asset Management
Boston,
Massachusetts
| – | -$874K | -96,600 | Closed |
|
|
RCM
31
Rotella Capital Management
Bellevue,
Washington
| – | -$155K | -17,118 | Closed |
|
32
Citigroup
New York
| – | -$758 | -80 | -99% |
|
ENZY Hedge Fund Activity: Q4 2015 in Review
30 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Enzymotec Ltd (ENZY) for Q4 2015, worth a combined $95.2M — up 14% from $83.4M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ENZY positions and 2 closed out — a net gain of 5 holders — while 7 added to existing stakes and 7 trimmed.
The largest buyer was Tiger Management, adding an estimated $3.39M. The largest seller was Summit Partners Public Asset Management, exiting entirely with an estimated $874K sold.
- 30 institutional investors held Enzymotec Ltd (ENZY) as of Q4 2015, up from 25 in Q3 2015.
- Funds reported $95.2M of Enzymotec Ltd stock for Q4 2015, up 14% quarter-over-quarter.
- 7 funds opened new Enzymotec Ltd positions in Q4 2015 and 2 closed out, a net change of +5 holders.
- The largest Enzymotec Ltd buyer in Q4 2015 was Tiger Management, an estimated $3.39M added.
- The largest Enzymotec Ltd seller in Q4 2015 was Summit Partners Public Asset Management, an estimated $874K sold.
Based on aggregated 13F filings for Q4 2015.